home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 11/29/23

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...
PSTV - Plus Therapeutics files to sell ordinary shares, warrants

2023-11-22 16:28:09 ET More on Plus Therapeutics Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript Plus Therapeutics climbs on FDA orphan drug tag for radiotherapy Biocept gains on licensing pact with Plus Therapeutics for cancer test Seeking Al...

PSTV - MCRB, CYTO and TGS among mid-day movers

2023-11-20 12:59:05 ET Gainers: Mira Pharmaceuticals ( MIRA ) +58% . YPF ADR ( YPF ) +39% . Altamira Therapeutics Ltd ( CYTO ) +39% . ProKidney Corp ( PROK ) +35% . Soluna Holdings ( SLNH ) +32% . Safety Shot ( SHOT ) +...

PSTV - Fortress Biotech, Plus Therapeutics among healthcare movers

2023-11-20 10:00:12 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Fortress Biote...
PSTV - LRHC, SGD and NSTG among pre-market losers

2023-11-20 08:24:45 ET Losers: Syntec Optics Holdings ( OPTX ) -15% . Safe and Green Development Corp ( SGD ) -14% . Plus Therapeutics ( PSTV ) -14% reports new interim reSPECT-GBM phase 2 trial data at the society for NeuroOncology annual meeting. ...

PSTV - Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 mon...

PSTV - Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it ...
PSTV - Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? PR Newswire NEW YORK , Nov. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, ...

PSTV - ARVL, PSTV and TALK among pre-market losers

2023-11-06 08:17:52 ET Losers: MoonLake Immunotherapeutics ( MLTX ) -30% . Tecnoglass ( TGLS ) -15% after Q3 earning release . Kodiak Sciences ( KOD ) -11% says Phase 3 trial for lead asset met key goals. Arrival ( ARVL ) -9% . A...

PSTV - 24/7 Market News Lunch Break 3 Nov 2023

2023-11-03 12:14:31 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (...
Previous 10 Next 10